Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mylan Suffers Several Setbacks: What's in Store in 2H18?

by Zacks Equity Research

Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

    by Zacks Equity Research

    Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

      Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

      by Zacks Equity Research

      Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

        Mylan (MYL) Launches Generic Version of Lilly's Adcirca

        by Zacks Equity Research

        Mylan (MYL) launches the first generic version of Lilly's Adcirca for the treatment of pulmonary arterial hypertension to improve exercise ability.

          What's in Store for Amgen (AMGN) in Second Half of 2018?

          by Zacks Equity Research

          After a relatively strong first half, let's see how things are poised for Amgen (AMGN) in the second half of the year.

            Kalyan Nandy headshot

            Top Research Reports: UnitedHealth, PepsiCo, Amgen & More

            by Kalyan Nandy

            Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH), PepsiCo (PEP) and Amgen (AMGN).

              Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2

              by Zacks Equity Research

              Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.

                Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

                by Zacks Equity Research

                Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.

                  Mylan (MYL) Q2 Earnings and Revenues Lag Estimates

                  by Zacks Equity Research

                  Mylan (MYL) delivered earnings and revenue surprises of -13.01% and -5.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                    Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?

                    by Zacks Equity Research

                    Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).

                      Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

                      by Zacks Equity Research

                      Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

                        Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up

                        by Zacks Equity Research

                        Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q2. Sales beat estimates.

                          Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?

                          by Zacks Equity Research

                          While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

                            AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up

                            by Zacks Equity Research

                            AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.

                              Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

                              by Zacks Equity Research

                              Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

                                Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up

                                by Zacks Equity Research

                                Glaxo (GSK) beats both earnings and revenues in the second quarter of 2018, and signs a four-year collaboration with 23andMe and invests $300 million for the same.

                                  Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

                                  by Zacks Equity Research

                                  While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

                                    Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

                                    by Zacks Equity Research

                                    Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.

                                      AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

                                      by Zacks Equity Research

                                      AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

                                        Kinjel Shah headshot

                                        Drug Pricing in Focus Again as Trump Tweet Slams Pfizer

                                        by Kinjel Shah

                                        In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".

                                          Is Mylan N.V. (MYL) a Great Stock for Value Investors?

                                          by Zacks Equity Research

                                          Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

                                            Adamis (ADMP) Surges Following Novartis Deal for Symjepi

                                            by Zacks Equity Research

                                            Shares of Adamis (ADMP) skyrocket after the company signs a commercialization deal with Novartis for Symjepi.

                                              Mylan, Lupin Collaborate for the Proposed Biosimilar Enbrel

                                              by Zacks Equity Research

                                              Mylan (MYL) enters a partnership with Lupin Limited to commercialize a biosimilar of blockbuster drug Enbrel on approval.

                                                Mylan (MYL) Up 10.2% Since Earnings Report: Can It Continue?

                                                by Zacks Equity Research

                                                Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Company News For Jun 6, 2018

                                                  by Zacks Equity Research

                                                  Companies in the news are: PANW,SBUX,MYL,HDS